

Press release from Emotra AB (publ)
Göteborg, 18 February 2022

Emotra AB (publ); Spotlight Stock Market has notified Emotra that they are halting the Company's ongoing re-listing process

Today, on 18 February 2022, Emotra AB ("Emotra" or "the Company") is disclosing that the Company has been informed by Spotlight Stock Market that the ongoing re-listing process has been halted. Spotlight has justified this decision by saying that Emotra has submitted incorrect information, which the Company denies.

Emotra is hereby announcing that the ongoing listing review at Spotlight Stock Market has been halted immediately. Spotlight Stock Market has justified this decision by saying that the Company has submitted incorrect information during the process. At Emotra, we are well aware that some erroneous answers to certain questions were submitted in connection with the background checks for individuals who represent NeuraMetrix Inc., but these errors have been corrected by the Company.

The Company will be submitting a more detailed explanation next week.

This information is the type of information that Emotra AB is legally obliged to publish in accordance with the EU market abuse regulation. This information was submitted for publication on 18 February 2022, at 05:29 PM under the above contact's supervision.

For further information about Emotra, please contact:

Daniel Poté, President, telephone: +46 73 234 41 93, E-mail: daniel@emotra.se

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of neurological research mental health. The Company's methods/products, NeuraMetrix TC and EDOR®, are unique, proprietary, and patent-protected.

EMOTRA AB, Färögatan 33, 164 51 Kista, Sweden
Tel: +46 732-34 41 93, www.emotra.se